Publicaciones en las que colabora con Fernando Escalante Barrigón (14)

2023

  1. Multiple myeloma with t(11;14): impact of novel agents on outcome

    Blood Cancer Journal, Vol. 13, Núm. 1

  2. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

    Cancers, Vol. 15, Núm. 5

  3. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

    Haematologica, Vol. 108, Núm. 10, pp. 2753-2763

2022

  1. MM-202 Impact of t(11;14) in Multiple Myeloma on Response to Treatment and Survival

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S413-S414

  2. Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival

    British Journal of Haematology, Vol. 198, Núm. 2, pp. 278-287

2021

  1. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

2020

  1. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

  2. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

    Blood Cancer Journal, Vol. 10, Núm. 10

2018

  1. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 18, Núm. 10, pp. e401-e419

2017

  1. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma

    Haematologica, Vol. 102, Núm. 5, pp. 922-931

2016

  1. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma

    Leukemia, Vol. 30, Núm. 10, pp. 2026-2031

  2. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

    Blood, Vol. 127, Núm. 24, pp. 3035-3039

2015

  1. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380

2014

  1. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma

    Blood, Vol. 124, Núm. 8, pp. 1300-1303